Zimmer price target raised to $113 from $105 at Cantor Cantor increased its price target on Zimmer after the company agreed to buy Biomet. The firm thinks that, beginning in the second year of the deal, Zimmer's accretion guidance could be slightly conservative. It keeps a Buy rating on the stock.
Zimmer downgraded to Hold from Buy at Brean Capital Brean Capital downgraded Zimmer to Hold saying uncertainty over 2016 earnings potential following the Biomet acquisition is likely to linger for several quarters. Brean sees little room for multiple expansion pending greater clarity.